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THE activation  of  complement  and  contact  systems
occurs  in  reperfusion  injuries  with  initial  tissue
hypoxia, and lactic acidosis such as mycardial infarc-
tion and birth asphyxia. The aim of our experiment
was  the  formal  proof  of  activation  by  sole  lactic
acidosis. Lactic acid was added to blood and plasma
samples from 10 healthy volunteers. C5a and factor
XIIa were measured by EIA after incubation at 37°C
for 1 h. Both concentrations increased (P < 0.0001 by
Friedman analysis) in blood and plasma samples with
increasing amount of added lactic acid. Lactic acidosis
can  activate  C5  from  the  complement  system  and
factor XII from the contact system directly, even in
the absence of cellular components.
Key words: Lactic acidosis, Complement system, Contact
system, Hageman factor, C5a
Introduction
Activation  of  complement  and  contact  system  has
been  described  in  reperfusion  injuries  with  tissue
hypoxia and lactic acidosis such as mycardial infarc-
tion, birth  asphyxia,  and gut  ischaemia.1–4 Contact
with membrane or mitochondrial fractions and other
subcellular components of destroyed cells as well as
reaction to other mediators and receptor changes may
cause  activation.  Complement  and  contact  system
participate in the pathogenesis of shock and tissue
injury after initial activation.1,2,4 The aim of this study
was to investigate the direct effect of lactic acidosis
on the activation of C5 from the complement system
and  on  factor  XII  from  the  contact  system  in
vitro.5,6,7. To distinguish the effect of cellular compo-
nents  on these  activations  we  performed our  tests
with blood and plasma.
Material and Methods
Twenty ml blood samples from 10 healthy volunteers
aged 25–40 years were collected in tubes with 400
I.E.  Heparin.  Heparin  blood  was  filled  into  six
polypropylene tubes of 1ml portions. The leftover of
14ml heparin blood was centrifuged immediately at
4°C for 10min at 3000g. The resulting plasma was
separated and filled into six tubes of 1ml portions.
Anhydrous lactate (Sigma-Aldrich, Deisenhofen, Ger-
many)  dissolved  in  steril  water  were  added  in
amounts  of  0.2mg  (2.2m mol),  0.5mg  (5.5m mol),
1mg (11.1m mol), or 2mg (22.2m mol) either to blood
or plasma sample and one blood and plasma sample
was left natively. All 10 portions were incubated in a
water bath at 37°C for 1h. One blood and one plasma
sample  were  centrifuged  before  incubation  and
stored  at    –80°C  to  be  used  as  start  value. After
incubation  1mg  disodium-ethylenediaminetetra-ace-
tic  acid  (EDTA)  was  added  to  stop  complement
activation5 and the samples were centrifuged, sepa-
rated  and  stored.  Blood-pH,  potassium  and  lactate
concentration were examined in the heparin blood
samples  before  and  after  lactate  addition  by  Ciba
Corning  865  (Fernwald,  Germany).  Changes  in
plasma pH-value by added lactic acid were similar as
in  blood  samples  and  therefore  not  reported
separately.
Reliability  of  test  results  was  monitored  using
controls  with  known  concentrations  of  C5a  and
factor  XIIa.  C5a  was  determined  with  a  specific
sandwich EIA8 (Fa. Behring, Marburg, Germany) and
showed a variation coefficient (n = 20) of 8%. The
concentration of activated factor XIIa was measured
by  a  semi-quantitative  direct  immunoassay9 (WAK-
Chemie  Medical  GmbH,  Bad  Homburg,  Germany),
and showed a variation coefficient (n = 20) of 6% .
Both  EIAs  did  not  depend  on  pH-value  in  the
sample.
Statistical analysis
As most data were not normally distributed, results
were  expressed as  median with  quartiles.  Changes
with increasing lactic acid concentrations were com-
pared with variance analysis (Friedman test). Differ-
ences  in  C5a  and  factor  XIIa  between  blood  and
plasma  were  assessed  by  multi  variance  analysis
(MANOVA)  for  repeated  measures.  Statistical  sig-
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were performed by means of the software package
SPSS-PC (Chicago, Illinois, USA).
Results
The influence of lactate addition on pH, base deficit,
measured  lactate,  and  potassium  concentrations  in
blood and C5a and factor XIIa concentrations in blood
and  plasma  are  shown  in  Table  1.  Lactate  and
potassium  concentration  as  well  as  base  deficit
increased with the amount of added lactic acid to the
samples (P < 0.0001). C5a and factor XIIa concentra-
tions  increased (P <  0.0001)  and  differences  were
found for C5a  (P < 0.001) and factor XIIa (P < 0.005)
between blood and plasma samples.
Discussion
The activation of complement and contact system is
reported in several conditions associated with tissue
acidosis.  After  birth  asphyxia  both  systems  were
activated in blood pH-values below 7.10.3 The lowest
value  of  the  pH  at  inflammatory  tissue  has  been
reported to be 5.5–6.5.10 The diagnostic criteria for
lactic acidosis include a pH less than 7.35 and blood
lactate concentration greater than 5mmol/l.11 There-
fore,  the  described  in  vitro model  investigates  in
clinical relevant ranges.
The  elevated  C5a  and  factor  XIIa  values  in  our
series indicate that lactic acidosis can activate parts of
the complement and contact  system in plasma and
blood. As shown by the similar rise in plasma samples,
no cellular interaction or contact with destroyed cells
is necessary to initiate the complement and contact
cascade in acidosis. The differences between heparin
blood  and  plasma  may  be  due  to  two  factors:  (1)
binding of C5a and factor XIIa to receptors of blood
cells,12 which  results  in lower C5a and factor  XIIa
values in blood compared with plasma by low amount
of added lactic acid; and (2) additional activation by
contact with destroyed cell membranes and receptor
changes in blood, which  results in higher C5a and
factor  XIIa  values  in  blood  samples  by  lower  pH
values causing cell destruction. This haemolytic effect
is documented by raising potassium concentration in
the samples.
Fishelson  et  al.13 reported  that  at  pH  6.4  the
generation  of  the  C3  convertase  of  the  alternative
pathway is increased in blood samples. The classical
pathway  and  the  plasma  contact  system  may  be
activated  by  conformational  changes  of  C-reactive
protein,  which  results  in  binding  to  negatively
charged  surfaces  in  acidosis.10 However,  the  C5
convertase, which are instrumental in activating C5
with the release of C5a, need a surface upon which
the tri-molecular complement protein complexes can
assemble.  Therefore,  the  development  of  C5a  in
J. Sonntag et al.
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)plasma samples is difficult to explain without granulo-
cytes.  Hammer  et  al.14 reported  a  complement
activation with cleavage of C5 in serum independent
of the classical or alternative pathway by pH 6.4, but
without development of C5a. Thus, our results may be
show that another proteinase is activated by acidosis
in plasma, which then cleaves C5 to C5a without any
role of the complement convertase. Alternatively, cells
remaining in the plasma might provide surfaces for
complement convertase assembly.
Conclusion
Lactic acidosis can activate parts of the complement
and  contact  system  directly,  even  in  absence  of
cellular components. Further studies should be direc-
ted to determine the mechanisms for activation of C5
and factor XII by lactic acidosis.
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